RxDoctor Payments DataLook up a doctor →

Kristin Highland, MD

Pulmonary Disease · Cleveland, OHNPI 1740384528

Payments from drug & device makers

$3,225,517in general payments, 2019–2025

Across 762 payments — averaging $4232.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.1M
  • Boehringer Ingelheim$479K
  • United Therapeutics Corporation$231K
  • Amgen$189K
  • Actelion Pharmaceuticals US, Inc.$138K
  • Boehringer Ingelheim International GmbH$78K
  • plus $36K from 11 others
$4,184in research payments, 2019–2025

Across 2 payments — averaging $2092.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$4K

What the payments were for

  • Consulting fees$120,04022%
  • Speaking & faculty fees$357,79765%
  • Travel & lodging$59,30611%
  • Food & beverage$13,3662%
  • Education$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,225,517 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$32,724
Medicare patients
192
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil133$3,160,899
OpsumitMacitentan154$1,942,485
OfevNintedanib Esylate77$1,028,917
UptraviSelexipag36$818,474
Orenitram ErTreprostinil Diolamine36$581,139
AdempasRiociguat39$533,558
WinrevairSotatercept-Csrk26$472,136
LetairisAmbrisentan21$260,514
Ambrisentan68$231,393
TreprostinilTreprostinil Sodium13$193,068
EsbrietPirfenidone13$139,375
Tadalafil90$97,223
AdcircaTadalafil20$83,784
Bosentan31$62,730
Sildenafil Citrate125$60,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$137,893$2,823,688221 claims
Boehringer IngelheimOfev$478,930$1,028,91777 claims
BayerAdempas$11,147$533,55839 claims
MerckWinrevair, Dulera$2,074,677$479,34539 claims
GileadLetairis$60$260,51421 claims
Genentech USA, Inc.Esbriet$564$139,37513 claims
United Therapeutics CorporationAdcirca$231,314$83,78420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →